Association between DPYD c.1129-5923 C %26gt; G/hapB3 and severe toxicity to 5-fluorouracil-based chemotherapy in stage III colon cancer patients: NCCTG N0147 (Alliance)

作者：Lee Adam M; Shi Qian; Alberts Steven R; Sargent Daniel J; Sinicrope Frank A; Berenberg Jeffrey L; Grothey Axel; Polite Blase; Chan Emily; Gill Sharlene; Kahlenberg Morton S; Nair Suresh G; Shields Anthony F; Goldberg Richard M; Diasio Robert B

来源：Pharmacogenetics and Genomics, 2016, 26(3): 133-137.

DOI：10.1097/FPC.0000000000000197

• 5-fluorouracil
• toxicity
• pharmacogenetics
• colon cancer
• polymorphism
• dihydropyrimidine dehydrogenase

Severe (grade >= 3) adverse events (AEs) to 5-fluorouracil (5-FU)-based chemotherapy regimens can result in treatment delays or cessation, and, in extreme cases, life-threatening complications. Current genetic biomarkers for 5-FU toxicity prediction, however, account for only a small proportion of toxic cases. In the current study, we assessed DPYD variants suggested to correlate with 5-FU toxicity, a deep intronic variant (c.1129-5923 C > G), and four variants within a haplotype (hapB3) in 1953 stage III colon cancer patients who received adjuvant FOLFOX +/- cetuximab. Logistic regression was used to assess multivariable associations between DPYD variant status and AEs common to 5-FU (5FU-AEs). In our study cohort, 1228 patients (62.9%) reported any grade >= 3 AE (overall AE), with 638 patients (32.7%) reporting any grade >= 3 5FU-AE. Only 32 of 78 (41.0%) patients carrying DPYD c.1129-5923 C > G and the completely linked hapB3 variants c.1236 C > G and c.959-51 T > C showed at least one grade >= 3 5FU-AE, resulting in no statistically significant association (adjusted odds ratio=1.47, 95% confidence interval=0.90-2.43, P=0.1267). No significant associations were identified between c.1129-5923 C > G/hapB3 and overall grade >= 3 AE rate. Our results suggest that c.1129-5923 C > G/hapB3 have limited predictive value for severe toxicity to 5-FU-based combination chemotherapy.

• 出版日期2016-3